Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - tablet - see ingredients - each tablet contains carbidopa 25 mg levodopa 250 mg

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - tablet - see ingredients - each tablet contains carbidopa equivalent to anhydrous carbidopa 25 mg levodopa 100 mg

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

organon south africa (pty) ltd - tablet - see ingredients - each tablet contains carbidopa monohydrate equivalent to 50 mg carbidopa levodopa 200 mg

Airija - anglų - HPRA (Health Products Regulatory Authority)

organon pharma (ireland) limited - carbidopa; levodopa - tablet - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - carbidopa monohydrate, quantity: 26.9 mg; levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; purified talc; sodium starch glycollate; microcrystalline cellulose; quinoline yellow aluminium lake; maize starch; magnesium stearate - treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa is frequently helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with parkinson's disease and syndrome.

Airija - anglų - HPRA (Health Products Regulatory Authority)

imbat limited - carbidopa levodopa - tablets - 10/100 milligram

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

merck sharp & dohme corp. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 10 mg - sinemet is indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on sinemet. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with sinemet. these inhibitors must be discontinued at least two weeks prior to initiating therapy with sinemet. sinemet may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - carbidopa monohydrate 27mg equivalent to carbidopa 25 mg; levodopa 100mg - modified release tablet - 25/100 - active: carbidopa monohydrate 27mg equivalent to carbidopa 25 mg levodopa 100mg excipient: ethanol hyprolose iron oxide red magnesium stearate polyvinyl acetate purified water

Naujoji Zelandija - anglų - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - carbidopa monohydrate 54mg equivalent to carbidopa 50 mg; levodopa 200mg; carbidopa monohydrate 54mg equivalent to carbidopa 50 mg; levodopa 200mg; carbidopa monohydrate 54mg equivalent to carbidopa 50 mg; levodopa 200mg - modified release tablet - 50/200 - active: carbidopa monohydrate 54mg equivalent to carbidopa 50 mg levodopa 200mg excipient: allura red ac hyprolose hypromellose indigo carmine magnesium stearate active: carbidopa monohydrate 54mg equivalent to carbidopa 50 mg levodopa 200mg excipient: hyprolose crotonic acid-polyvinylacetate copolymer iron oxide red magnesium stearate quinoline yellow aluminium lake active: carbidopa monohydrate 54mg equivalent to carbidopa 50 mg levodopa 200mg excipient: hyprolose crotonic acid-polyvinylacetate copolymer iron oxide red magnesium stearate quinoline yellow aluminium lake - idiopathic parkinson's disease postencephalitic parkinsonism symptomatic parkinsonism (carbon monoxide or manganese intoxication) patients with parkinson's disease or parkinsonism who are taking vitamin preparations that contain pyridoxine to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterised by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

Izraelis - anglų - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - tablets controlled release - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.